In this study, we tested the eVect of intratumoral administration of dendritic cells (DCs) with inducible expression of diVerent cytokines, using the novel Rheoswitch Therapeutic System on the experimental models of renal cell cancer (RENCA) and MethA sarcoma. Intratumoral injection of DCs, engineered to express IL-12, IL-21, or IFN-, showed potent therapeutic eVect against established tumor. This eVect was associated with the induction of potent tumor antigen-speciWc CD8 + T-cell responses, as well as the inWltration of tumors with CD4 + and CD8 + T cells but not with the cytotoxic activity of DCs. Combination of i.t. administration of DCs, producing diVerent cytokines, did not enhance the antitumor eVect of therapy with single cytokine. These results indicate that RTS can be a potent tool for conditional topical cytokine delivery, in combination with DC administration. However, combination of diVerent cytokines may not necessarily improve the outcome of treatment.
Introduction
Combination of dendritic cell (DC) based vaccines, with cytokine support, was always considered a promising approach to cancer immunotherapy. However, direct administration of diVerent cytokines to patients is associated with toxicity, which limited their clinical utility. Therefore, genetic modiWcation of DCs, engineered to produce diVerent cytokines, was tested in diVerent pre-clinical models and clinical trials [1, 2] . The development of new methods of cytokine delivery, based upon conditional regulation of their release, opened a new opportunity for therapeutic intervention. Recently, the Rheoswitch Therapeutic System (RTS) has been developed by Intrexon [3] . This system consists of two fusion proteins. The Wrst, Gal4-EcR, contains a modiWed ecdysone receptor (EcR) that is fused with the DNA binding domain of the yeast Gal4 transcription factor. The second, VP16-RXR, consists of a chimeric RXR fused with the transcription activation domain of the VP16 protein of HSV1. The chimeric RXR heterodimerizes eYciently with the Gal-4EcR. Activator ligand (AL) binds speciWcally to EcR and stabilizes heterodimerization between the two fusion proteins, forming an active transcription factor, which induces the transcription of speciWc cytokines placed under the control of an inducible promoter containing Gal4-binding sites. Thus, RTS provides a universal gene regulation system for gene and cell therapies that require precise control of gene expression to improve safety and eYcacy. In the absence of the AL, cytokine production is not detectable from the engineered DCs.
Various strategies are used to deliver tumor-associated antigens with dendritic cells [4] [5] [6] . Tumor cells are the best source of tumor-associated antigens. However, the mere presence of DCs in the vicinity of tumor is insuYcient to induce antitumor responses. Immune responses were generated only after combination of intratumoral (i.t.) administration of DCs with radiation or chemotherapy in pre-clinical settings [7] [8] [9] [10] and in phase I clinical trials [11] [12] [13] . Cytokine support appears to be able to bypass the requirements for tumor radiation, since i.t. injection of DCs transduced with IL-12 or IL-32 resulted in potent antitumor eVect [14] [15] [16] .
Induction of potent antitumor immune responses involves multiple cytokines; therefore, it is possible that administration of several cytokines may provide more superior clinical results than the single one. New RTS technology opened the possibility for testing of this hypothesis using DC platform.
Materials and methods

Mice
Female 6-8 week-old Balb/c mice were purchased from NCI and maintained in microisolator cages. Recognized principles of laboratory animal care were followed (Guide for the Care and Use of Laboratory Animals, National Research Council, 1996), and animal protocols were approved by the University of South Florida Animal Care and Use Committee.
Cell lines and tumor models
The renal adenocarcinoma cell line, RENCA, was maintained in RPMI containing 10% FBS, 0.5% penicillinstreptomycin, 1% non-essential amino acids, 1% sodium pyruvate, and 0.1 M -mercaptoethanol. The murine Wbrosarcoma cell line, MethA, was propagated in culture in DMEM containing 0.5% penicillin-streptomycin, 11% sodium pyruvate, and 0.1 M -mercaptoethanol with 10% FBS. The cells were grown as an ascitic tumor in a Balb/c mouse and, after being withdrawn from the mouse, were washed and injected into the experimental mice subcutaneously. Balb/c mice were subcutaneously inoculated with 1 £ 10 6 RENCA or Meth A cells on day 0. Mice were split into various treatment groups around day 10, when the tumors reached an approximate size of 5 mm in diameter. The mice were treated with single intratumoral (i.t.) injections of 5 £ 10 6 transduced DCs. Mice also received i.p. injections of 50 mg/kg activator ligand (AL) in DMSO that were initiated a day before DC administration. In other groups, AL was administered orally with mouse diet. AL was administered for 2 weeks, starting a day prior to DC treatment. Tumor size was determined 3 days a week and recorded as mm 2 by determining the product of the largest diameters measured by calipers.
Viral vectors
The VQAd-Rheo-sp1 adenoviral vectors encoding mIL-12, IL-21, or IFN-that are conditionally activated by a small molecule diacylhydrazine ligand were produced and provided by Intrexon. The RheoSwitch Therapeutic System (RTS) was developed as previously described [14] .
Generation of DCs and transduction with adenovirus DCs were generated from murine bone marrow (BM), using 7-day culture in complete RPMI medium supplemented with 20 ng/ml GM-CSF and 10 ng/ml IL-4 (R&D Systems). DCs were washed in serum-free medium and infected with diVerent adenoviruses (Ad) provided by Intrexon. Infection was performed at DC concentration, 5 £ 10 6 /ml, for 2 h in serum-free medium, followed by reconstitution of the medium to 10% FBS and DC concentration to 10 6 /ml. Cells were cultured for an additional 24 h before intratumoral (i.t.) injection. The viral dose required to produce a high level of cytokines was determined in previous and preliminary experiments. Based on the results of those experiments, we used an adenovirus concentration of 5,000 vp/cell.
IFN-elispot assay
To measure immune response, MethA sarcoma-bearing mice were used. ELISPOT plates (Millipore) were coated with a 2 g/ml coating antibody (IFN-) (BD, Invitrogen). The following day, spleen cells from the various treatment groups were added at a 4 £ 10 5 cells/well. The MethA sarcoma-associated mutant p53-derived speciWc peptide (KYICNSSCM) or control peptide (SIYRYYGL) was added at a concentration of 10 g/ml. The mutant p53-derived peptide binds the MHC class I molecule and therefore is recognized by CD8 + T cells [17] . Spleen cells were incubated overnight at 37°C. Subsequently, plates were washed and incubated with biotinylated detection IFN--speciWc antibody (BD, Invitrogen) for 2 h at room temperature, followed by Streptavidin-HRP. TMB substrate (Sigma) was used to visualize the results, and counting was performed using an automatic ELISPOT reader (Cellular Technology).
Immunohistochemistry
RENCA tumor-bearing mice were sacriWced 2 days after completion of the treatment; the tumors were harvested and kept frozen in liquid nitrogen. Frozen sections were generated and stained, using antibodies against CD4 or CD8 (BD Biosciences) and the ABC vectastain kit (Vector labs). The cells were counterstained, using hematoxylin, and mounted. The number of cells was counted per mm 2 .
Statistical analysis
Analysis of tumor growth curves was performed, using a two-way ANOVA test with a Bonferroni posttest. Descriptive statistics, like the number of INF-producing T cells and immunohistochemistry, were analyzed using Student t test. P value <0.05 were considered signiWcant.
Results and discussion
To determine the best route for administrated AL, to induce cytokine production, we compared the daily i.p. injections of AL and the oral administration with chow. The RENCA mouse tumor model of renal cell cancer was used in our study. Tumors were established s.c. and DCs, transduced with IL-12, were injected i.t. with activator delivered for 15 days. Treatment of mice in control groups, with AL alone or with DC-IL-12 without AL, did not signiWcantly aVect tumor growth (Fig. 1a) . In contrast, treatment of mice with DC-IL-12 and AL resulted in a substantial slow down of the tumor growth (Fig. 1a) . However, the eVect of i.p. administration of activator was rather modest. The statistical signiWcance was seen only on day 42, after tumor inoculation. A two-way ANOVA test of the all groups did not reach statistical signiWcance. The eVect of AL delivered as chow provided a more potent eVect with a statistically signiWcant (P = 0.03) diVerence from all control groups (Fig. 1a) . Our data were consistent with previous observation with i.t. injection of DC-IL-12 made in diVerent tumor models [14] . Because AL in chow demonstrated a higher potency than i.p. in all subsequent experiments, the chow form of AL was used.
IL-21 and IFN-are two cytokines that are important for the generation of immune responses but have not been previously tested in combination with i.t. DC therapy. In our experiments, DC-IL-21 showed strong antitumor activity, with statistically signiWcant diVerences between DC-IL-21 + AL group and all control groups (P = 0.01) (Fig. 1b) . A similar eVect was observed in mice treated with DC-IFN-(P < 0.001 between AL and DC-IFN-+ AL groups and P < 0.03 between untreated and DC-IFN-+ AL P < 0.03) (Fig. 1c) . Thus, DC-IL-12, DC-IL-21, and DC-IFN-provided signiWcant antitumor activity against RENCA-bearing mice.
Given the observed therapeutic beneWts of IL-12, IL-21, and IFN-as monotherapies, we tested the hypothesis that the combination of IL-12 with sequential administration of other cytokines that may target diVerent types of cells can provide a better therapeutic response than each cytokine alone. In all combination experiments, AL and DC-IL-12 were administered the same way as in the experiments described in Fig. 1a . DC-IL-21 or DC-IFN-were administered 4-5 days later. AL was delivered for 18 days. The combination of AL and DC-IL-12 had a strong antitumor eVect, similar to that observed in previous experiments (Fig. 1d, e) . Treatment of mice with DC-IL-21 and AL had no antitumor activity, probably due to the 4-day delay with administration of DC-IL-21 (Fig. 1d) . The combination of DC-IL-12 with DC-IL-21 had a strong antitumor eVect, but it was not diVerent for the eVect of DC-IL-12 + AL. No potentiating eVect of two cytokines was seen (Fig. 1d) . Similar experiments were performed for the combination of IL-12 and IFN-. In contrast to the experiments with IL-21, delay with DC-Ad-IFN administration did not interfere with the antitumor eVect of therapy. Treatment with DC-IFN + AL showed strong antitumor eVect (P < 0.01). However, the combination of DC-IL-12 and DC-IFN did not demonstrate stronger antitumor activity than individual cytokine (Fig. 1e) . Thus, the combination of cytokines did not enhance the antitumor eVect of the therapy.
Next, we asked what could be the possible mechanism of the antitumor eVect of the DC-cytokine therapy. In order to address this question, we used a MethA sarcoma model with a deWned tumor-associated antigen (TAA): p53-derived peptide epitope. We had previously demonstrated that the combination of DC-p53 vaccine with recombinant IL-12 improved the antitumor eVect of the therapy in this model [17] . First, we conWrmed that treatment of MethA sarcoma with DC-IL-12 and AL resulted in a potent antitumor eVect (Fig. 2a) . To assess the tumor-speciWc nature of immune responses in treated mice, we measured T-cell response to MethA using p53-derived or control MHC class I bound peptides in IFN ELISPOT assay. A signiWcant p53-speciWc response was detected only in the group of mice treated with a combination of DC-IL-12 and AL (Fig. 2b) . Thus, antitumor activity of DC-IL-12 was associated with the generation of tumor-speciWc immune responses. To assess tumor inWltration by T cells, we collected tumors 10 days after the start of therapy. Very few T cells were seen in the control groups of mice. In contrast, mice treated with DC-IL-12 and AL demonstrated a strong inWltration of both CD4 + and CD8 + T cells (Fig. 2c) . In recent years, myeloid-derived suppressor cells (MDSC) were demonstrated to play a major role in limiting the eVect of cancer immunotherapy [18] . It was suggested that IL-12 could reduced MDSC expansion in tumor-bearing mice and, thus, enhance the eVect of the therapy [19] . To test this possibility, we evaluated the MDSC level in spleens of mice treated with an eVective combination of DC-IL-12, DC-IFN-, and AL. Our data showed that, despite the fact that this therapy had very potent antitumor activity, it did not aVect the level of MDSC in this model (Fig. 2d) .
We also tested the possibility that DC transduced with IL-12 could have direct antitumor activity. We used cytotoxicity in chromium release assay against RENCA tumor cells. DC-IL-12 cells treated with AL had very little toxicity against tumor not unlike the DCs from any other groups (Fig. 2e) .
Thus, our data demonstrated that a novel RTS system, for conditional delivery of several tested cytokines, Fig. 1 EVect of intratumoral administration of DCs with conditional expression of combination of diVerent cytokines on tumor growth. a Mice bearing RENCA tumors, with an average size of about 50 mm 2 , were separated into diVerent treatment groups on day 10 after tumor inoculation. DC-IL-12 were injected on day 10 and the administration of AL started on day 9 and continued for 15 days. Each group included 7-10 mice. DiVerences between mice, treated with DC-IL-12+ AL chow and all control groups, were statistically signiWcant (P < 0.03). b, c Experiments were performed essentially the same way as in Fig. 1a , with the exception of the use of DC-IL-21 (b) or DC-INF-(c) instead of DC-IL-12. Each group included 6-8 mice. The diVerences between the DC-IL-21 + AL or DC-IFN-+ AL groups and the controls group were statistically signiWcant (P = 0.01 and P < 0.001, respectively). d, e Mice with established RENCA tumor were treated with i.t. injection of DC-IL-12 on day 14, followed by administration of DC-IL-21 (d) or DC-IFN-(e) 4 days later. AL was administered from day 13 until day 31. Each group included 6-8 mice. The diVerences between the combination cytokines + AL groups and all control groups were signiWcant (P < 0.04). However, no diVerences were seen with DC-IL-12 + AL group (P > 0.1) We selected several cytokines with known activity in antitumor immune responses. IL-12 role in positive regulation of antitumor immune responses is well established [20] . IL-21 can reverse the suppressive eVects of regulatory T cells (Tregs) on CD8 + T cells, thereby enhancing the host immunity against tumors [21] . A population of DCs generated by fusion of IL-21 and GM-CSF has been shown to generate tumor antigen-speciWc response [22] . There have been recent studies demonstrating that type I interferon IFN production, acting on CD8 + DCs and enhancing their ability to cross-present antigen, is required for eVective activation of tumor antigen-speciWc CD8 + T cells [23, 24] . We expected that these cytokines would support induction of potent antitumor immune responses, which would translate into antitumor activity. Our data have supported this hypothesis. We also suggested that combination of diVerent cytokines may provide additional therapeutic beneWts. IL-12 up-regulates critical signaling intermediates like JAK-STAT that sensitizes host immune cells to lower doses of IFN-, leading to signiWcantly enhanced survival of tumor-bearing mice [25] . Therefore, we hypothesized that using DC-IL-12 as the primary step of treatment would sensitize mice to the antitumor eVects of IFN-leading to increased eYcacy and decreased toxicity. We also hypothesized that combination of IL-12, that promotes expansion and activity CTLs, and IL-21, that can neutralizes Tregs, would enhance antitumor eVect of DC administration. However, contrary to the initial hypothesis, our data demonstrated that the combination of diVerent cytokines did not necessarily result in an enhanced antitumor eVect of therapy. It is possible that there is a certain threshold of T-cell reactivity that can be reached by DCs producing individual cytokines and combination of selected cytokines was not able to enhance it further. In this situation, the limitations of antitumor activity of the therapy could be not the result of ineYcient T-cell responses but rather presence of other mechanisms of tumor escape. These factors associated with tumor microenvironment may include immune suppressive cytokines, receptors, and molecules like indolamine 2,3-dioxygenase, peroxynitrite, etc. [26] [27] [28] .
